GBT's drug meets trial goal, investors skeptical of speedy approval

(Reuters) - Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.